Brendan P. Eckelman Ph.D.
Net Worth
Last updated:
What is Brendan P. Eckelman Ph.D. net worth?
The estimated net worth of Dr. Brendan P. Eckelman Ph.D. is at least $61,799,245 as of 28 May 2024. He owns shares worth $39,917,719 as insider, has earned $19,522,526 from insider trading and has received compensation worth at least $2,359,000 in Inhibrx Biosciences, Inc..
What is the salary of Brendan P. Eckelman Ph.D.?
Dr. Brendan P. Eckelman Ph.D. salary is $589,750 per year as Founder, Chief Scientific Officer & Executive Vice President of Corporation Strategy in Inhibrx Biosciences, Inc..
How old is Brendan P. Eckelman Ph.D.?
Dr. Brendan P. Eckelman Ph.D. is 46 years old, born in 1979.
What stocks does Brendan P. Eckelman Ph.D. currently own?
As insider, Dr. Brendan P. Eckelman Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | Founder, Chief Scientific Officer & Executive Vice President of Corporation Strategy | 1,735,553 | $23 | $39,917,719 |
What does Inhibrx Biosciences, Inc. do?
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
Brendan P. Eckelman Ph.D. insider trading
Inhibrx Biosciences, Inc.
Dr. Brendan P. Eckelman Ph.D. has made 33 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 300,000 units of INBX stock worth $10,290,000 on 28 May 2024.
The largest trade he's ever made was exercising 300,000 units of INBX stock on 28 May 2024. As of 28 May 2024 he still owns at least 1,735,553 units of INBX stock.
Inhibrx Biosciences key executives
Inhibrx Biosciences, Inc. executives and other stock owners filed with the SEC:
- Dr. Brendan P. Eckelman Ph.D. (46) Founder, Chief Scientific Officer & Executive Vice President of Corporation Strategy
- Dr. Klaus W. Wagner (52) Chief Medical Officer & Executive Vice President
- Mr. Mark Paul Lappe (57) Founder, Chairman, Pres & Chief Executive Officer